Moderna (MRNA) EPS (Weighted Average and Diluted) (2019 - 2026)
Moderna (MRNA) reported EPS (Weighted Average and Diluted) of -$3.4 for Q1 2026, down 34.92% year-over-year from -$5.22 in Q1 2025, and down 61.14% quarter-over-quarter from -$2.11 in Q4 2025.
Moderna (MRNA) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Moderna (MRNA) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$3.4 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$3.4, down 34.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.15 (up 6.64% YoY), and the FY2025 annual result was -$7.26, up 21.77% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$3.4 in Q1 2026 per MRNA's latest filing, from -$2.11 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $8.58 in Q1 2022 and troughed at -$9.53 in Q3 2023.
- A 5-year average of -$0.73 and a median of -$2.11 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2025: EPS (Weighted Average and Diluted) jumped 202.11% in 2022, then sank 1800.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.66 in 2022, then slumped by 84.7% to $0.56 in 2023, then plunged by 619.64% to -$2.91 in 2024, then climbed by 27.49% to -$2.11 in 2025, then sank by 61.14% to -$3.4 in 2026.
- Business Quant data shows MRNA's EPS (Weighted Average and Diluted) at -$3.4 in Q1 2026, -$2.11 in Q4 2025, and -$0.51 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Moderna | 25.27 Bn | 20.06 Bn | -566.00 Mn | -3.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 |
| Dec 31, 2025 | -2.11 |
| Sep 30, 2025 | -0.51 |
| Jun 30, 2025 | -2.13 |
| Mar 31, 2025 | -2.52 |
| Dec 31, 2024 | -2.91 |
| Sep 30, 2024 | 0.03 |
| Jun 30, 2024 | -3.33 |
| Mar 31, 2024 | -3.07 |
| Dec 31, 2023 | 0.56 |
| Sep 30, 2023 | -9.53 |
| Jun 30, 2023 | -3.62 |
| Mar 31, 2023 | 0.19 |
| Dec 31, 2022 | 3.66 |
| Sep 30, 2022 | 2.53 |
| Jun 30, 2022 | 5.24 |
| Mar 31, 2022 | 8.58 |
| Dec 31, 2021 | 11.29 |
| Sep 30, 2021 | 7.70 |
| Jun 30, 2021 | 6.46 |